Things are about to change in sickle cell disease

And we’ve got an expert to explain how.

Later today, we’re going to talk to Dr. Cindy Neunert, pediatric hematologist and associate professor of pediatrics at Columbia University, about how the standard of care in sickle cell is poised to change, with on-the-horizon therapies from Novartis, Global Blood Therapeutics, Bluebird Bio, and more.

We’ll discuss clinical data, patient needs, doctor preferences, and the future of a disease that currently has few effective treatments. If you’d like to listen in, subscribe to STAT Expert Advantage and check back this afternoon.